Aarti Drugs gets 7 inspectional USFDA observations for Tarapur facility

Written By :  Ruchika Sharma
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2024-09-23 05:30 GMT   |   Update On 2024-09-23 05:30 GMT

 Maharashtra: Aarti Drugs Limited has announced that the United States Food and Drug Administration (US FDA) has issued 7 inspectional observations in Form 483 for the API manufacturing facility of the Company at Plot No. E-22, MIDC, Tarapur, Maharashtra.

The inspection was conducted from 12th to 20th of September 2024.
"On conclusion of the inspection, the company has received 7 inspectional observations in Form 483, where none of the observations are related to Data Integrity," the Company stated in a BSE filing.

 An FDA Form 483 is issued to firm management at the conclusion of an inspection when an investigator(s) has observed any conditions that in their judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts. 

"The company will work closely with US FDA in resolving all points. There is no impact on financial, operation or other activities of the Company pursuant the observations received," it added.
Advertisement

Aarti Drugs Ltd. was established in the year 1984 and forms part of $900 Million Aarti Group of Industries with R&D Division at Tarapur, Maharashtra Industrial Development Corporation (MIDC) in close vicinity to manufacturing locations.

The Company is engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs), Pharma Intermediates, Specialty Chemicals and also produces Formulations with its wholly-owned subsidiary – Pinnacle Life Science Private Limited. Products under APIs includes Ciprofloxacin Hydrochloride, Metronidazole, Metformin HCL, Ketoconazole, Ofloxacin etc. whereas Specialty Chemicals includes Benzene Sulphonyl Chloride, Methyl Nicotinate etc.


Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News